Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Only the patients meeting all the following criteria can be eligible to participate in the trial:~1. Histologically and/or cytologically confirmed stage IV non-small cell lung cancer and ALK fusion~2. At least one measurable lesion 3 No history of any systemic anti-tumor therapy.~4. Agreement on providing formalin fixed tumor tissue specimen or fresh biopsy tissue from tumor lesions after diagnosis of metastasis 6. Age of 18-75 years 7. ECOG Scores 0-1; 8. Expected survival ≥ 3 months;~Exclusion Criteria:~1. Known allergy to recombinant humanized anti-PD-1 monoclonal antibody drug and its components;~2. Histologically or cytopathologically confirmed combination with small cell lung cancer component or sarcomatoid lesion;~3. Current participation in and receiving other study treatment, or participation in treatment of one study drug within 4 weeks prior to administration of JS001;~4. Previous use of systematic chemotherapy for advanced NSCLC; targeted therapy for advanced NSCLC~5. Previous use of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cells synergetic stimulation or checkpoint pathway, such as IDO, IL-2R, GITR);~6. Chest (lung) radiotherapy \> 30 Gy within 6 months prior to the start of study treatment.~7. Active tuberculosis (TB), receiving anti-tuberculosis therapy currently or within one year prior to screening;~8. Known active central nervous system (CNS) metastasis and/or cancerous meningitis;~9. Spinal cord compression for which operation and/or radical radiotherapy has not been given, or no clinical evidence of stable disease for ≥4 weeks prior to enrollment after treatment for previously diagnosed spinal cord compression~10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage~11. Uncontrollable or symptomatic hypercalcemia~12. Clinically uncontrolled active infection, including but not limited to acute pneumonia;~13. Uncontrollable major epileptic seizure or superior vena cava syndrome~14. Previous or current combination with other malignancies ;~15. History of idiopathic pulmonary fibrosis, organized pneumonia (e.g., obliterating bronchiolitis), drug induced pneumonia, idiopathic pneumonia or evidence of active pneumonia during chest CT scanning for screening;~16. Known hepatic diseases of clinical significance, including active viral hepatitis, alcoholic hepatitis or other hepatitis, liver cirrhosis, fatty liver, hereditary liver disease;~17. Use of systemic immunosuppressive therapy for any active autoimmune disease within two years prior to Day 1 of the 1st cycle;~18. Vaccination of live-virus vaccine within 30 days after the start of planned treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group TORIPALIMAB combined with standard chemotherapy (Type: EXPERIMENTAL): None
- Group Placebo combined with standard chemotherapy (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).